Nasdaq · CIK 0001501697
XFOR X4 Pharmaceuticals, Inc
Insider trading from SEC Form 4. Last filing 8 d ago. Close $2.82 on Oct 12, 2026, +2% from the 52-week low and -40% from the high.
In brief
X4 Pharmaceuticals, Inc (XFOR) has 40 SEC Form 4 filings on file from 16 insiders, the latest filed on Oct 5, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 3 open-market sells worth $354k, net -$354k.
16 open-market trades have been scored at XFOR. The newest: David Kirske (Chief Financial Officer) sold $34k of stock on Oct 1, 2026, filed Oct 5, 2026, scored 28 (weak). The largest of the 16 shown: Adam R Craig (Executive Chairman) bought $250k on Oct 23, 2025, scored 47 (moderate). 2 insiders sold within 14 days of each other around Aug 12, 2026.
18 Form 144 notices of planned sales are on file, the latest filed Oct 1, 2026.
Last 90 days
Net insider value
-$354k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$354k by 3 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
XFOROct 12, 2026 · close 2.82
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at X4 Pharmaceuticals, Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | David Kirske Chief Financial Officer sell | $34k 11,767 shares | -7% | 0% from low-39% from high | |
| 45Moderate | Adam R Craig Executive Chairman sell | $211k 47,436 shares | -13% | +72% from low-8% from high | |
| 38Weak | John Volpone President sell | $109k 24,576 shares | -8% | +72% from low-8% from high | |
| 28Weak | David Kirske Chief Financial Officer sell | $36k 8,543 shares | -5% | +229% from low0% from high | |
| 30Weak | David Kirske Chief Financial Officer sell | $73k 16,961 shares | -9% | +206% from low-7% from high | |
| 47Moderate | Adam R Craig Executive Chairman buy | $250k 86,206 shares | +30% | +118% from low-87% from high | |
| 33Weak | Mark Baldry Chief Commercial Officer buy | $2,561 1,032 shares | +4% | 0% from low-88% from high | |
| 21Weak | Mark Baldry Chief Commercial Officer buy | $19k 35,050 shares | +37% | - | |
| 20Weak | Christophe Arbet-Engels Chief Medical Officer sell | $5,284 11,624 shares | -45% | - | |
| 15Weak | Mark Baldry Chief Commercial Officer sell | $13k 29,159 shares | -24% | - | |
| 15Weak | Mary DiBiase Chief Operating Officer sell | $10k 22,258 shares | -4% | - | |
| 5Weak | Paula Ragan President and CEO sell | $13k 31,897 shares | -3% | - | |
| 5Weak | Paula Ragan President and CEO sell | $18k 31,897 shares | -3% | - | |
| 20Weak | Mark Baldry Chief Commercial Officer sell | $7,488 10,257 shares | -29% | +9% from low-70% from high | |
| 27Weak | Mary DiBiase Chief Operating Officer sell | $49k 67,695 shares | -18% | +9% from low-70% from high | |
| 48Moderate | Adam S. Mostafa Chief Financial Officer sell | $168k 230,645 shares | -74% | +9% from low-70% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 1, 2026 | David Kirske Officer | 11,767 0.01% of outstanding | $34k | Oct 1, 2026 | none |
| Aug 13, 2026 | Adam Craig Executive Chaiman | 47,436 0.05% of outstanding | $216k | Aug 12, 2026 | none |
| Aug 13, 2026 | John Volpone Officer | 24,576 0.02% of outstanding | $112k | Aug 12, 2026 | none |
| May 12, 2026 | David Kirske Officer | 16,961 0.02% of outstanding | $73k | May 12, 2026 | none |
| Jan 24, 2025 | Arbet-Engels Christophe Officer | 11,624 0.01% of outstanding | $6,044 | Jan 24, 2025 | none |
| Jan 24, 2025 | Baldry Mark Officer | 29,159 0.02% of outstanding | $15k | Jan 24, 2025 | none |
| Jan 24, 2025 | DiBiase Mary Officer | 22,258 0.01% of outstanding | $12k | Jan 24, 2025 | none |
| Jan 24, 2025 | Mostafa Adam S. Officer | 74,773 0.04% of outstanding | $39k | Oct 7, 2024 | none |
| Jan 24, 2025 | Ragan Paula Officer | 76,473 0.04% of outstanding | $40k | Jan 24, 2025 | $13k |
| Jan 24, 2025 | Taveras Arthur Officer | 24,828 0.01% of outstanding | $13k | Jan 24, 2025 | none |
| Nov 15, 2024 | Ragan Paula Officer | 31,897 0.02% of outstanding | $13k | Nov 15, 2024 | $149k |
| Oct 15, 2024 | Ragan Paula Officer | 31,897 0.02% of outstanding | $18k | Oct 15, 2024 | $132k |
| Nov 3, 2023 | Ragan Paula Officer | 39,906 0.02% of outstanding | $32k | Nov 3, 2023 | $145k |
| Nov 1, 2023 | Baldry Mark Officer | 10,257 0.01% of outstanding | $8,144 | Nov 1, 2023 | none |
| Nov 1, 2023 | DiBiase Mary Officer | 67,695 0.04% of outstanding | $54k | Nov 1, 2023 | $3,299 |
| Nov 1, 2023 | Mostafa Adam S. Officer | 230,645 0.14% of outstanding | $182k | Nov 1, 2023 | none |
| Nov 1, 2023 | Ragan Paula Officer | 199,531 0.12% of outstanding | $158k | Nov 1, 2023 | none |
| Nov 1, 2023 | Taveras Arthur Affiliate | 67,695 0.04% of outstanding | $54k | Nov 1, 2023 | none |
Transactions
The newest 50 of 51 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | David Kirske Chief Financial Officer | SOpen-market sale Common Stock | -11,767 | $2.86 | $34k | 155,983 | 8 d ago |
| Aug 12, 2026 | Adam R Craig Executive Chairman | SOpen-market sale Common Stock | -47,436 | $4.44 | $211k | 328,651 | Aug 13, 2026 |
| Aug 12, 2026 | John Volpone President | SOpen-market sale Common Stock | -24,576 | $4.44 | $109k | 265,305 | Aug 13, 2026 |
| Jul 1, 2026 | Kelly Gold director | AGrant or award Stock Option (right to buy)derivative | +110,000 | $0.00 | $0 | 110,000 | Jul 1, 2026 |
| Jun 30, 2026 | David Kirske Chief Financial Officer | SOpen-market sale Common Stock | -8,543 | $4.26 | $36k | 167,750 | Jul 1, 2026 |
| May 12, 2026 | David Kirske Chief Financial Officer | SOpen-market sale Common Stock | -16,961 | $4.29 | $73k | 176,293 | May 13, 2026 |
| Jan 1, 2026 | Gary Bridger director | AGrant or award Stock Option (right to buy)derivative | +110,000 | $0.00 | $0 | 0 | Jan 7, 2026 |
| Jan 1, 2026 | Michael S Wyzga director | AGrant or award Stock Option (right to buy)derivative | +110,000 | $0.00 | $0 | 0 | Jan 5, 2026 |
| Jan 1, 2026 | Francoise de Craecker director | AGrant or award Stock Option (right to buy)derivative | +110,000 | $0.00 | $0 | 0 | Jan 5, 2026 |
| Jan 1, 2026 | Murray Stewart director | AGrant or award Stock Option (right to buy)derivative | +110,000 | $0.00 | $0 | 0 | Jan 5, 2026 |
| Oct 29, 2025 | Adam R Craig Executive Chairman | AGrant or award Stock Option (right to buy)derivative | +2,329,154 | $0.00 | $0 | 2,329,154 | Oct 31, 2025 |
| Oct 29, 2025 | David Kirske Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +1,552,769 | $0.00 | $0 | 1,552,769 | Oct 31, 2025 |
| Oct 29, 2025 | John Volpone President | AGrant or award Stock Option (right to buy)derivative | +2,329,154 | $0.00 | $0 | 2,329,154 | Oct 31, 2025 |
| Oct 23, 2025 | Adam R Craig Executive Chairman | POpen-market purchase Common Stock | +86,206 | $2.90 | $250k | 376,087 | Oct 27, 2025 |
| Aug 14, 2025 | David Kirske Chief Financial Officer | AGrant or award Common Stock | +193,254 | $0.00 | $0 | 193,254 | Aug 14, 2025 |
| Aug 14, 2025 | John Volpone President | AGrant or award Common Stock | +289,881 | $0.00 | $0 | 289,881 | Aug 14, 2025 |
| Aug 14, 2025 | Adam R Craig Executive Chairman | AGrant or award Common Stock | +289,881 | $0.00 | $0 | 289,881 | Aug 14, 2025 |
| Aug 12, 2025 | Adam R Craig Executive Chairman | AGrant or award Stock Option (right to buy)derivative | +1,609,873 | $0.00 | $0 | 1,609,873 | Aug 14, 2025 |
| Aug 12, 2025 | David Kirske Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +1,073,249 | $0.00 | $0 | 1,073,249 | Aug 14, 2025 |
| Aug 12, 2025 | John Volpone President | AGrant or award Stock Option (right to buy)derivative | +1,609,873 | $0.00 | $0 | 1,609,873 | Aug 14, 2025 |
| Aug 14, 2025 | Adam R Craig Executive Chairman | AGrant or award Stock Option (right to buy)derivative | +529,201 | $0.00 | $0 | 529,201 | Aug 14, 2025 |
| Aug 14, 2025 | David Kirske Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +352,800 | $0.00 | $0 | 352,800 | Aug 14, 2025 |
| Aug 14, 2025 | John Volpone President | AGrant or award Stock Option (right to buy)derivative | +529,201 | $0.00 | $0 | 529,201 | Aug 14, 2025 |
| May 20, 2025 | Natasha Fay Thoren Chief Legal Officer | AGrant or award Common Stock | +3,333 | $0.00 | $0 | 9,462 | Jul 3, 2025 |
| Jun 9, 2025 | Gary Bridger director | AGrant or award Common Stock | +1,500 | $0.00 | $0 | 4,722 | Jun 10, 2025 |
| Jun 9, 2025 | David W J McGirr director | AGrant or award Common Stock | +1,500 | $0.00 | $0 | 4,722 | Jun 10, 2025 |
| Jun 9, 2025 | Murray Stewart director | AGrant or award Common Stock | +1,500 | $0.00 | $0 | 7,883 | Jun 10, 2025 |
| Jun 9, 2025 | Michael S Wyzga director | AGrant or award Common Stock | +1,500 | $0.00 | $0 | 5,555 | Jun 10, 2025 |
| Jun 9, 2025 | Keith Woods director | AGrant or award Common Stock | +1,500 | $0.00 | $0 | 6,000 | Jun 10, 2025 |
| Jun 9, 2025 | Francoise de Craecker director | AGrant or award Common Stock | +1,500 | $0.00 | $0 | 4,722 | Jun 10, 2025 |
| May 16, 2025 | Mark Baldry Chief Commercial Officer | AGrant or award Common Stock | +1,032 | $2.48 | $2,561 | 25,337 | Jun 3, 2025 |
| May 16, 2025 | Mark Baldry Chief Commercial Officer | POpen-market purchase Common Stock | +1,032 | $2.48 | $2,561 | 25,337 | May 20, 2025 |
| Feb 12, 2025 | Christophe Arbet-Engels Chief Medical Officer | AGrant or award Common Stock | +850,000 | $0.00 | $0 | 864,207 | Feb 14, 2025 |
| Feb 12, 2025 | Mary DiBiase Chief Operating Officer | AGrant or award Common Stock | +650,000 | $0.00 | $0 | 1,140,980 | Feb 14, 2025 |
| May 17, 2024 | Mark Baldry Chief Commercial Officer | POpen-market purchase Common Stock | +21,646 | $0.68 | $15k | 115,769 | Feb 14, 2025 |
| Nov 15, 2024 | Mark Baldry Chief Commercial Officer | POpen-market purchase Common Stock | +13,404 | $0.34 | $4,598 | 129,173 | Feb 14, 2025 |
| Feb 12, 2025 | Mark Baldry Chief Commercial Officer | AGrant or award Common Stock | +600,000 | $0.00 | $0 | 729,173 | Feb 14, 2025 |
| Jan 23, 2025 | Christophe Arbet-Engels Chief Medical Officer | AGrant or award Common Stock | +25,831 | $0.00 | $0 | 25,831 | Jan 27, 2025 |
| Jan 23, 2025 | Mark Baldry Chief Commercial Officer | AGrant or award Common Stock | +74,773 | $0.00 | $0 | 123,282 | Jan 27, 2025 |
| Jan 23, 2025 | Mary DiBiase Chief Operating Officer | AGrant or award Common Stock | +61,178 | $0.00 | $0 | 513,238 | Jan 27, 2025 |
| Jan 24, 2025 | Christophe Arbet-Engels Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -11,624 | $0.45 | $5,284 | 14,207 | Jan 27, 2025 |
| Jan 24, 2025 | Mark Baldry Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -29,159 | $0.45 | $13k | 94,123 | Jan 27, 2025 |
| Jan 24, 2025 | Mary DiBiase Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -22,258 | $0.45 | $10k | 490,980 | Jan 27, 2025 |
| Nov 15, 2024 | Paula Ragan President and CEO | SOpen-market sale Common Stock10b5-1 | -31,897 | $0.39 | $13k | 993,919 | Nov 19, 2024 |
| Oct 15, 2024 | Paula Ragan President and CEO | SOpen-market sale Common Stock10b5-1 | -31,897 | $0.56 | $18k | 1,025,816 | Oct 16, 2024 |
| Nov 1, 2023 | Mark Baldry Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -10,257 | $0.73 | $7,488 | 24,690 | Nov 3, 2023 |
| Nov 1, 2023 | Mary DiBiase Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -67,695 | $0.73 | $49k | 310,844 | Nov 3, 2023 |
| Nov 1, 2023 | Adam S. Mostafa Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -230,645 | $0.73 | $168k | 80,221 | Nov 3, 2023 |
| Oct 31, 2023 | Mark Baldry Chief Commercial Officer | AGrant or award Common Stock | +34,947 | $0.00 | $0 | 34,947 | Nov 2, 2023 |
| Oct 31, 2023 | Mary DiBiase Chief Operating Officer | AGrant or award Common Stock | +230,645 | $0.00 | $0 | 378,539 | Nov 2, 2023 |
50 of 51 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Christophe Arbet-EngelsChief Medical Officer
- Mark BaldryChief Commercial Officer
- Gary Bridgerdirector
- Adam R CraigExecutive Chairman
- Mary DiBiaseChief Operating Officer
- Kelly Goldcfo, officer, director
- David KirskeChief Financial Officer
- David W J McGirrdirector
- Adam S. MostafaChief Financial Officer
- Paula RaganPresident and CEO
- Murray Stewartdirector
- Natasha Fay ThorenChief Legal Officer
- John VolponePresident
- Michael S Wyzgadirector
- Keith Woodscoo, officer, director
- Francoise de Craeckerdirector
Questions about XFOR
Answered from the filings on this page, as of the latest one.
Are insiders buying XFOR?
As of Oct 5, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 3 open-market sells worth $354k by 3 insiders at X4 Pharmaceuticals, Inc in the last 90 days, net -$354k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade XFOR on the open market?
David Kirske (Chief Financial Officer) sold $34k of XFOR on Oct 1, 2026 and filed the Form 4 on Oct 5, 2026. InsiderTell scored 28 (weak).
How many insiders file Form 4 at X4 Pharmaceuticals, Inc?
16 people have filed a Form 4 at X4 Pharmaceuticals, Inc, among them Christophe Arbet-Engels (Chief Medical Officer), Mark Baldry (Chief Commercial Officer), Gary Bridger (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.